GH3595 / Genhouse Bio - LARVOL DELTA

Discovery of GH3595: a novel allosteric DHX9 inhibitor for cancer therapy (AACR 2025) - "In summary, we report the discovery and characterization of GH3595, a potent and selective inhibitor of DHX9, which effectively disrupts DHX9-mediated signaling pathways. These findings highlight its significant therapeutic potential for the treatment of malignancies characterized by microsatellite instability or deficiencies in homologous recombination."

Breast Cancer • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • BRCA • MSI